How medications for opioid use disorder affect brain inflammation and cognition in people with HIV
Effects of Medication for Opioid Use Disorder on Microglial Activation and Neurocognition in People Living with HIV
This study is looking at how different medications for opioid use disorder affect the immune system in the brains of people living with HIV, to see if these treatments can help improve brain health and thinking skills.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11121918 on NIH RePORTER |
What this research studies
This research investigates the impact of various medications for opioid use disorder on immune activation in the brain of individuals living with HIV. It aims to understand how these medications influence the behavior of immune cells, particularly myeloid cells, and their potential effects on cognitive function. By analyzing cerebrospinal fluid and using advanced genomic techniques, the study seeks to uncover the relationship between opioid treatment and brain health in this population. The findings could provide insights into optimizing treatment strategies for those affected by both HIV and opioid use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are also receiving treatment for opioid use disorder.
Not a fit: Patients who do not have HIV or who are not undergoing treatment for opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options that enhance cognitive function and reduce inflammation in people living with HIV who also struggle with opioid use disorder.
How similar studies have performed: Previous research has indicated that opioid antagonists may have beneficial effects on neuroinflammation, suggesting that this approach could yield significant insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Farhadian, Shelli — Yale University
- Study coordinator: Farhadian, Shelli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.